Efficacy and Safety of Afatinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with EGFR Mutations: A Meta-Analysis of Real-World Evidence

<div>The meta-analysis results for disease control rates (DCRs) and objective response rates (ORRs) in different dose groups after afatinib treatment in advanced NSCLC with EGFR mutation: (a) comparison of DCRs in different dose groups and (b) comparison of ORRs in different dose groups.</div>

Journal of Oncology

fig7

Figure 7

Figure 7: Efficacy and Safety of Afatinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with EGFR Mutations: A Meta-Analysis of Real-World Evidence 

Figure 7 | Efficacy and Safety of Afatinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with EGFR Mutations: A Meta-Analysis of Real-World Evidence 